Efficacy and involvement gut microbiota of atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma.

Efficacy and involvement gut microbiota of atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma. - Efficacy and involvement gut microbiota of atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043934

Enrollment

Registered

2021-04-15

Start date

2021-04-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable advanced hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with unresectable advanced hepatocellular carcinoma 2. Patients who have not received any prior systemic therapy 3. Patients whose physician has suggested and agreed to atezolizumab plus bevacizumab as the optimal treatment

Exclusion criteria

Exclusion criteria: 1. Patients with impaired liver reserve (Child-Pugh class C) 2. Patients with refractory ascites 3. Patients judged ineligible by the principal investigator and sub-investigators 4. Patients for whom local therapy is indicated

Design outcomes

Primary

Measure	Time frame
Association with gut microbiota composition and efficacy of atezolizumab and bevacizumab therapy in patients with unresectable advanced hepatocellular carcinoma.	—

Secondary

Measure	Time frame
Incidence of adverse events, concentration of cytokines and chemokines in the blood, and ratio of tumor immune-related cells in the blood.	—

Countries

Japan

Contacts

Public ContactTomotake Shirono

Kurume university Gastroenterology

shirono_tomotake@med.kurume-u.ac.jp0942-31-7561

Outcome results